Lantern

Lantern was born out of collaboration with researchers from Stanford and other top universities. It wasn't just another 'meditation' app; it was a structured program designed to treat anxiety and depression through evidence-based CBT. The Churn Problem Initially, Lantern charged individuals about $49/month. However, mental health apps face a unique paradox: when users feel better, they stop using the app; when they don't feel better quickly enough, they also stop using the app. This led to a 'leaky bucket' where Lantern had to spend massive amounts of money on Facebook and Google ads just to replace the users they were losing every month. The Failed Pivot By 2017, the company realized that the consumer market was a race to the bottom. They pivoted to the 'Employer' market, hoping companies would pay for Lantern as a benefit for their staff. While the feedback from HR departments was positive, the 'Sales Cycle' was lethal. Large companies take a year or more to sign a contract, and Lantern's venture capital 'runway' simply wasn't long enough to wait for those checks to clear. The Asset Sale In August 2018, CEO Alejandro Foung announced that Lantern would cease its commercial operations. Instead of a messy bankruptcy, the company executed a 'soft landing' by selling its intellectual property and clinical content to its partners, including 23andMe and Omada Health. The Legacy Lantern remains a respected name in the HealthTech world because they proved that digital CBT could work as well as in-person therapy. However, its death served as a warning to the industry: Clinical rigor does not protect you from broken unit economics. Today, many of the features pioneered by Lantern live on inside larger, more diversified healthcare platforms.